Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2023-04-25 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
2022年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Effectiveness Self-Evaluation Report" for the year 2022 by Beijing Nuosiland Biotechnology Co., Ltd. It discusses the company's internal control systems, evaluation scope, control environment, risk assessment, control activities, information and communication, and control supervision. It includes detailed descriptions of internal control deficiencies and their classifications, as well as conclusions on the absence of major defects. The document is a comprehensive report on internal control effectiveness rather than a general annual report or audit report. It does not appear to be a brief announcement or a certification letter but a substantive report on internal control evaluation. Such reports typically fall under the category of Audit Report / Information (AR), as they relate to internal control assessments and compliance with regulatory internal control standards, distinct from full annual reports or financial statements. FY 2022
2023-04-25 Chinese
2022年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage and actual use of raised funds by Beijing Northland Biotech Co., Ltd. It includes specifics about the amount raised, usage, management, and compliance with regulatory requirements. It references approvals from the China Securities Regulatory Commission, details on the issuance of shares, and includes audit and verification reports from accounting firms. The document also discusses the management of idle raised funds, investment in financial products, and confirms no misuse of funds. The content is focused on the use and management of capital raised through stock issuance, which aligns with a Capital/Financing Update. The document is over 6,000 characters and contains substantive financial and operational data related to fundraising and capital use, not just an announcement or certification. Therefore, it fits best under the Capital/Financing Update (CAP) category.
2023-04-25 Chinese
关于部分变更募集资金用途的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the partial change in the use of previously raised funds by Beijing Northland Biotech Co., Ltd. It includes specifics about the original fundraising, the amounts raised, the projects funded, and the reasons for reallocating funds among different clinical trial projects. It also details the decision-making process, including board and supervisory approvals, independent director opinions, and the need for shareholder meeting approval. The document focuses on the use and reallocation of capital raised through share issuance and does not present financial statements or earnings data. It is not a full annual or interim report, nor is it a simple announcement of a report publication. The content aligns with updates on company fundraising and capital usage, which fits the category of Capital/Financing Update (CAP). The document length is 4453 characters, which is sufficient for a substantive update rather than a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2023-04-25 Chinese
董事换届公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the change in the company's board of directors, detailing nominations for the new board members and independent directors, their qualifications, and the compliance with relevant laws and company regulations. It includes information about the board re-election process and the impact on the company. There are no financial statements or performance data, nor is it a report or presentation. The content clearly fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2023-04-25 Chinese
独立董事关于第五届董事会第二十三次会议相关事项的独立意见公告
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on various company matters discussed at the 23rd meeting of the 5th board of directors. It covers opinions on profit distribution, audit firm appointment, executive compensation, use of raised funds, internal control evaluation, stock option plans, changes in raised funds usage, board nominations, loan applications, and project changes. The document is a formal announcement of independent directors' opinions on resolutions to be submitted to the shareholders' meeting. It does not contain financial statements or detailed financial data but rather opinions and approvals related to governance and corporate actions. The document length is 3887 characters, which is relatively short and consistent with an announcement or opinion statement rather than a full report. This fits best with the category of Regulatory Filings (RNS), as it is a regulatory announcement of independent directors' opinions on board meeting matters and proposals for shareholder approval, not a full annual report, audit report, or management report.
2023-04-25 Chinese
中审亚太会计师事务所北京诺思兰德生物技术股份有限公司内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" which translates to "Internal Control Assurance Report". It includes detailed auditor's opinion on the effectiveness of internal controls related to financial reporting as of December 31, 2022. The report references auditing standards and internal control evaluation criteria, and it is issued by a certified public accounting firm. The content focuses on internal control evaluation, deficiencies, and related disclosures rather than full financial statements or annual performance. This matches the description of an Audit Report / Information (AR), which includes standalone audit reports and internal control assessments, excluding full annual reports. The document length is substantial and contains detailed evaluation, not just an announcement or certification letter, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the correct classification is AR with high confidence. FY 2022
2023-04-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.